MedDataX Logo

N- Acetylcysteine in Airway Clearance in Broncheictasis

NCT ID: NCT07293884

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis . Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity.

Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Broncheictasis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

broncheictasis N-acetylecysteine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IV N Acetyle cysteine

Intervention: N Acetyle cysteine given by IV injection

Group Type ACTIVE_COMPARATOR

N Acetyle cysteine given by IV injection

Intervention Type DRUG

Arm: IV N Acetyle cysteine

Nebulized N Acetyle cysteine

Intervention: Nebulized N Acetyle cysteine

Group Type ACTIVE_COMPARATOR

Nebulized N Acetyle cysteine

Intervention Type DRUG

Arm: Nebulized N Acetyle cysteine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

N Acetyle cysteine given by IV injection

Arm: IV N Acetyle cysteine

Intervention Type DRUG

Nebulized N Acetyle cysteine

Arm: Nebulized N Acetyle cysteine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects aged above 18 years old; with a diagnosis of bronchiectasis who are admitted to chest department due to acute exacerbation

Exclusion Criteria

* current smokers, a known allergy to N-acetylcysteine; pregnancy or lactation (for women); primary diagnosis of COPD or asthma
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sahar Refaat Mahmoud

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NAcetylcysteine broncheictasis

Identifier Type: -

Identifier Source: org_study_id